LUF5484

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: LUF5484
• 英文别名: (2-amino-4,5,6,7-tetrahydro-benzo[b]thiophen-3-yl)-(3,4-dichloro-phenyl)-methanone；(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(3,4-dichlorophenyl)methanone；(2-amino-4,5,6,7-tetrahydro-1-benzothiophen-3-yl)-(3,4-dichlorophenyl)methanone
• 化学式: C₁₅H₁₃Cl₂NOS
• 分子量: 326.246
• InChiKey: VBHZVGMOPSACQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  71.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  LUF5484 、 环丙甲酰丙酮 在 硫酸 乙腈 作用下， 以 溶剂黄146 为溶剂， 反应 0.17h， 以Preparative HPLC (30% CH3CN/H20) afforded 18 mg (23%) cyclopropyl-[(4-(3,4-dichloro-phenyl)-2-methyl-5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3-b]pyridin-3-yl)]-methanone as a light brown solid的产率得到cyclopropyl-(4-(3,4-dichloro-phenyl)-2-methyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-b]pyridin-3-yl)-methanone
  参考文献：
  名称：

  Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors

  摘要：

  本发明涉及公式I的化合物，其中R1，R2，R3，R4和R5如规范中所定义。本发明的化合物对GABAB受体具有活性，并且可用于治疗各种中枢神经系统疾病，包括焦虑症、抑郁症、癫痫、精神分裂症、认知障碍、痉挛和骨骼肌肌肉僵硬、脊髓损伤、多发性硬化症、肌萎缩侧索硬化、脑瘫、神经病性疼痛和与可卡因和尼古丁有关的渴望、精神病、惊恐障碍、创伤后应激障碍和胃肠疾病。

  公开号：

  US07390903B2
• 作为产物：
  描述：

  3,4-二氯苯甲酰乙腈 、 环己酮 在 吗啉 、 sulfur 作用下， 以 乙醇 为溶剂， 反应 48.0h， 以78%的产率得到LUF5484
  参考文献：
  名称：

  WO2006/63732

  摘要：

  公开号：

文献信息

• THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS
  申请人：Bardiot Dorothée

  公开号：US20120059028A1

  公开（公告）日：2012-03-08

  The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.

  本发明涉及一系列具有抗病毒活性的化合物，更具体地说是具有抑制人类免疫缺陷病毒（HIV）复制的特性。本发明还涉及制备这种化合物的方法，以及在这些合成步骤中有用的新型中间体。本发明还涉及含有这种化合物作为活性成分的有效剂量的制药组合物。此外，本发明还涉及将这种化合物用作药物或用于制造对治疗患有病毒感染，特别是HIV感染的动物有用的药物。此外，本发明还涉及通过给予治疗量的这种化合物的管理，可选地与一个或多个具有抗病毒活性的其他药物结合，用于治疗动物的病毒感染的方法。
• Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors
  申请人：Bardiot Dorothée

  公开号：US08785638B2

  公开（公告）日：2014-07-22

  The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.

  本发明涉及一系列具有抗病毒活性的化合物，更具体地说是具有抑制人类免疫缺陷病毒(HIV)复制的性质。本发明还涉及制备这种化合物的方法，以及在这些合成步骤中有用的新中间体。本发明还涉及包含这种化合物作为活性成分的有效量药物组合物。本发明进一步涉及将这种化合物用作药物或制造药物，用于治疗患有病毒感染的动物，特别是HIV感染。本发明还涉及通过给予这种化合物的治疗剂量，可选地与一种或多种具有抗病毒活性的其他药物联合使用，治疗动物的病毒感染的方法。
• Allosteric Modulation of the Adenosine A₁ Receptor. Synthesis and Biological Evaluation of Novel 2-Amino-3-benzoylthiophenes as Allosteric Enhancers of Agonist Binding
  作者：Pieter A. M. van der Klein、Angeliki P. Kourounakis、Ad P. IJzerman

  DOI：10.1021/jm991051d

  日期：1999.9.1

  Novel allosteric enhancers of agonist binding to the rat adenosine Al receptor are described. The lead compound for the new series was PD 81,723 ((2-amino-4,5-dimethyl-3-thienyl)[3(trifluoromethyl)phenyl]methanone), a compound previously reported by Bruns and co-workers (Mol. Pharmacol. 1990, 38, 950-958). The 4,5-dimethyl group and the benzoyl moiety were targets for further modifications, leading to series of 4,5-dialkyl (12a-g), of tetrahydrobenzo (12h-u), and of tetrahydropyridine (13a-g) derivatives. A number of compounds, in particular 12b, 12e, 12j, 12n, and 12u, proved superior to PD 81,723, Their EC50 values for enhancing the binding of the adenosine Al receptor agonist N-6-cyclopentyladenosine to the receptor were lower, and/or their antagonistic activity on the adenosine Al receptor was shown to be diminished.
• THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1828199B1

  公开（公告）日：2009-05-06
• THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS
  申请人：Katholieke Universiteit Leuven

  公开号：EP2430029B1

  公开（公告）日：2018-01-10